Novartis Ag (NVSEF) Property, Plant & Equipment (Net) Growth (3y) (2016 - 2025)
Novartis Ag (NVSEF) Property, Plant & Equipment (Net) Growth (3y) (2016 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
PP&E (Net) Growth (3y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
5.76% |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
36.02% |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
4.87% |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
4.87% |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
5.34% |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
14.59% |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
0.96% |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
4.40% |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
6.84% |
| 10 |
Novartis Ag |
- |
- |
- |
- |
| Date | Value |
|---|
| Dec 31, 2025 |
0.06% |
| Jun 30, 2025 |
827.72% |
| Dec 31, 2024 |
-87.99% |
| Jun 30, 2024 |
-7.62% |
| Dec 31, 2023 |
-8.11% |
| Jun 30, 2023 |
646.71% |
| Dec 31, 2022 |
466.08% |
| Jun 30, 2022 |
-33.40% |
| Mar 31, 2022 |
-32.88% |
| Dec 31, 2021 |
56.38% |
| Jun 30, 2021 |
-9.73% |
| Dec 31, 2020 |
587.33% |
| Dec 31, 2019 |
77.73% |
| Jun 30, 2018 |
125,779.14% |
| Dec 31, 2016 |
-33,368.57% |
